Merck & Co., Inc. (MRK) Profit Breakdown
- 2026-06-30: Pharmaceutical segment $13.03B; Animal Health segment $1.06B.
- 2025-06-30: Pharmaceutical segment $12.45B; Animal Health segment $987.00M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2007-12-31 to 2026-06-30
- Data captured
Profit by product
Gross margin: each quarter (3 month)
| Quarter end | Pharmaceutical segment | Animal Health segment |
|---|---|---|
| 2026-06-30 | $13.03B derived | $1.06B derived |
| 2025-06-30 | $12.45B derived | $987.00M derived |
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest: each quarter (3 month)
| Quarter end | Pharmaceutical segment | Animal Health segment |
|---|---|---|
| 2026-06-30 | $11.61B | $636.00M |
| 2025-06-30 | $11.10B | $593.00M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |